Yang J Q, Wei T, Chen Y W, Bai X L, Liang T B
Department of Hepatopancreatobiliary Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Key Laboratory of Pancreatic Disease of Zhejiang Province, Hangzhou 310009, China.
Zhonghua Wai Ke Za Zhi. 2017 May 1;55(5):396-400. doi: 10.3760/cma.j.issn.0529-5815.2017.05.018.
The morbidity of pancreatic ductal adenocarcinoma (PDAC) has been increasing over years, while the treatment efficacy and prognosis of PDAC remain far from satisfying. The newly-ermerged tumor immunotherapy has not only made lots of breakthroughs in various malignancies, but also brought an opportunity to the treatment of pancreatic cancer.PDAC immunotherapies, mainly including vaccine therapy, adoptive T cell thanfer therapy, checkpoint blockade therapy, have achieved a certain effect, however, the clinical outcomes have not been satisfactory. Therefore, the combination of immunotherapies based on different theoretical views is important and is likely to be the trend in the future. Carcinoma associated fibroblast (CAF) is the most common cell in pancreatic cancer stromal component. It will be helpful to develop more potential therapeutic targets by further exploring CAF and the mechanism of fibrosis mediated immunosuppression.
近年来，胰腺导管腺癌（PDAC）的发病率一直在上升，而PDAC的治疗效果和预后仍远不尽人意。新出现的肿瘤免疫疗法不仅在各种恶性肿瘤中取得了许多突破，也为胰腺癌的治疗带来了契机。PDAC免疫疗法主要包括疫苗疗法、过继性T细胞转移疗法、检查点阻断疗法，已取得了一定效果，然而，临床结果并不令人满意。因此，基于不同理论观点的免疫疗法联合应用很重要，且可能是未来的发展趋势。癌相关成纤维细胞（CAF）是胰腺癌基质成分中最常见的细胞。进一步探索CAF及其介导免疫抑制的纤维化机制，将有助于开发更多潜在的治疗靶点。
